These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 20506031)
1. Antibodies to aquaporin-4 in non-small cell lung cancer: a study on 50 patients. Jarius S; Warth A; Wandinger KP; Schnabel PA; Hoffmann H; Wildemann B; Muley T Neurol Sci; 2010 Dec; 31(6):871-2. PubMed ID: 20506031 [No Abstract] [Full Text] [Related]
2. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. Winter SF; Sekido Y; Minna JD; McIntire D; Johnson BE; Gazdar AF; Carbone DP J Natl Cancer Inst; 1993 Dec; 85(24):2012-8. PubMed ID: 8246287 [TBL] [Abstract][Full Text] [Related]
3. Potential application of non-small cell lung cancer-associated autoantibodies to early cancer diagnosis. Yao Y; Fan Y; Wu J; Wan H; Wang J; Lam S; Lam WL; Girard L; Gazdar AF; Wu Z; Zhou Q Biochem Biophys Res Commun; 2012 Jul; 423(3):613-9. PubMed ID: 22713465 [TBL] [Abstract][Full Text] [Related]
4. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916 [TBL] [Abstract][Full Text] [Related]
6. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Brichory FM; Misek DE; Yim AM; Krause MC; Giordano TJ; Beer DG; Hanash SM Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9824-9. PubMed ID: 11504947 [TBL] [Abstract][Full Text] [Related]
7. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Türeci O; Mack U; Luxemburger U; Heinen H; Krummenauer F; Sester M; Sester U; Sybrecht GW; Sahin U Cancer Lett; 2006 May; 236(1):64-71. PubMed ID: 15992994 [TBL] [Abstract][Full Text] [Related]
8. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826 [TBL] [Abstract][Full Text] [Related]
9. Strong association between P53 protein accumulation, serum antibodies and gene mutation in non-small cell lung cancer. Niklinska W; Burzykowski T; Laudanski J; Chyczewska E; Chyczewski L; Niklinski J Folia Histochem Cytobiol; 2001; 39(2):51-6. PubMed ID: 11374839 [TBL] [Abstract][Full Text] [Related]
10. [Autoimmune reactions in patients with various tumor localizations]. Kologrivova EN; Ivanova NV; Klimov VV; Lebedev MP; Choĭnzonov EL; Kolomiets SA; Kolomiets LA Vopr Onkol; 2000; 46(1):61-3. PubMed ID: 10789226 [TBL] [Abstract][Full Text] [Related]
11. Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases. Neri M; Betta P; Marroni P; Filiberti R; Cafferata M; Mereu C; Ivaldi G; Montanaro F; Puntoni R; Paganuzzi M Lung Cancer; 2003 Feb; 39(2):165-72. PubMed ID: 12581569 [TBL] [Abstract][Full Text] [Related]
12. [Serum anti-P53 antibodies (AB-anti-P53) in patients with advanced non-small cell lung cancer (NSCLC)]. Skrzypski M; Szymanowska A; Janowicz A; Dziadziuszko R; Ramlau R; Kozielski J; Pilarska-Machowicz A; Dobrzańska Z; Bigda J; Krzakowski M; Jassem E; Jassem J Pneumonol Alergol Pol; 2002; 70(7-8):353-8. PubMed ID: 12708076 [TBL] [Abstract][Full Text] [Related]
13. Efficient identification and use of tumor-associated antibodies as markers of non-small cell lung cancer. Zhong L; Peng X; Hidalgo GE; Doherty DE; Stromberg AS; Hirschowitz EA Chest; 2004 May; 125(5 Suppl):105S-6S. PubMed ID: 15136442 [No Abstract] [Full Text] [Related]
14. [Diagnosis of paraneoplastic polyneuropathy in patients with breast cancer and small cell lung cancer]. Koroleva ES; Losenkov IS; Alifirova VM; Ivanova SA; Goldberg VE; Novikova NS Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(4):93-6. PubMed ID: 24874327 [TBL] [Abstract][Full Text] [Related]
15. Serum anti-p53 antibodies in lung cancer: comparison with established tumor markers. Cioffi M; Vietri MT; Gazzerro P; Magnetta R; D'Auria A; Durante A; Nola E; Puca GA; Molinari AM Lung Cancer; 2001; 33(2-3):163-9. PubMed ID: 11551411 [TBL] [Abstract][Full Text] [Related]
16. Serum anti-p53 antibodies in patients with lung cancer. Mack U; Ukena D; Montenarh M; Sybrecht GW Oncol Rep; 2000; 7(3):669-74. PubMed ID: 10767388 [TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of circulating anti-p53 antibodies in lung cancer--a review. Kumar S; Mohan A; Guleria R Eur J Cancer Care (Engl); 2009 May; 18(3):248-54. PubMed ID: 19432918 [TBL] [Abstract][Full Text] [Related]
19. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Blaes F; Klotz M; Huwer H; Straub U; Kalweit G; Schimrigk K; Schäfers HJ Ann Thorac Surg; 2000 Jan; 69(1):254-8. PubMed ID: 10654525 [TBL] [Abstract][Full Text] [Related]
20. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients. Ohue Y; Eikawa S; Okazaki N; Mizote Y; Isobe M; Uenaka A; Fukuda M; Old LJ; Oka M; Nakayama E Int J Cancer; 2012 Sep; 131(5):E649-58. PubMed ID: 22109656 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]